Современные возможности терапии хронической крапивницы у детей

Chronic urticaria in children is one of the diseases that are underestimated in their severity and impact on the quality of life. The world academic literature data gives very little information on epidemiology, etiology of chronic urticaria, and researches on application of various therapies in children with the studied disease. Second-generation antihistamines are the leading medications in the therapy of chronic urticarial; however, there are not enough studies on the use of other treatment options in children with this pathology. Resistance to standard therapy and to high doses of antihistamines is one of the problems of managing both adult patients and children. Omalizumab is the first generation of biologicals drug for treating chronic urticaria resistant to standard therapy; the pharmaceutical can be administered in children over 12 years. Further research on the drug efficacy in chronic urticaria is required including safety rate evaluation in the pediatric group of patients.